Abstract
Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Current Pharmaceutical Design
Title:Current Rapid-Onset Antidepressants and Related Animal Models
Volume: 24 Issue: 22
Author(s): Kuo Yan, Yi-Bing Chen, Jia-Rong Wu, Kuang-Dai Li and Yuan-Lu Cui*
Affiliation:
- Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 88 YuQuan Road, Nankai District, Tianjin, 300193,China
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Abstract: Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Export Options
About this article
Cite this article as:
Yan Kuo, Chen Yi-Bing , Wu Jia-Rong, Li Kuang-Dai and Cui Yuan-Lu *, Current Rapid-Onset Antidepressants and Related Animal Models, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180727115222
DOI https://dx.doi.org/10.2174/1381612824666180727115222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Editorial (Thematic Issue : What is Language? Different Viewpoints)
Neuroscience and Biomedical Engineering (Discontinued) The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary
Central Nervous System Agents in Medicinal Chemistry Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science A Primary Reduced TCA Flux Governs Substrate Oxidation in T2D Skeletal Muscle
Current Diabetes Reviews Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs
Drug Design Reviews - Online (Discontinued) Diazo Ethers: Formation and Decomposition in the Course of Reactions Between Arenediazonium Ions and Different Alcohols
Mini-Reviews in Organic Chemistry MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Aging of the Innate Immune System: An Update
Current Immunology Reviews (Discontinued) Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Current Enzyme Inhibition Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Design, Synthesis, <i>In Silico</i> and <i>In Vitro</i> Studies of Substituted 1, 2, 3, 4- Tetrahydro Pyrimidine Phosphorus Derivatives
Combinatorial Chemistry & High Throughput Screening Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer´s Disease
Current Protein & Peptide Science Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder
Current Psychiatry Reviews Muscarinic Receptors as a Target for Drugs Treating Schizophrenia
Current Drug Targets - CNS & Neurological Disorders High-Frequency rTMS to Treat Refractory Binge Eating Disorder and Comorbid Depression: A Case Report
CNS & Neurological Disorders - Drug Targets